PUNE, India, November 22, 2016 /PRNewswire/ --
ReportsnReports.com adds "Muscular Dystrophy - Pipeline Review, H22016" to its store, providing comprehensive information on the therapeutics under development for Muscular Dystrophy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.
Muscular dystrophy is a group of diseases in which muscle fibers are unusually susceptible to damage. These damaged muscles become progressively weaker. Symptoms usually appear before age 6 and may appear as early as infancy. They may include fatigue, learning difficulties, intellectual disability, muscle weakness and progressive difficulty walking.
Complete report on Global Muscular Dystrophy Market Research with 44 market data tables and 15 figures, spread across 144 pages is available at http://www.reportsnreports.com/reports/755879-muscular-dystrophy-pipeline-review-h2-2016.html .
Company Analysis and Positioning discussed in this research are Acceleron Pharma, Inc., AMO Pharma Limited, Asahi Kasei Pharma Corp., aTyr Pharma, Inc., Benitec Biopharma Limited, Bio Blast Pharma Ltd., Biophytis SAS, Corcept Therapeutics Incorporated, Evotec AG, F. Hoffmann-La Roche Ltd., Genethon, Ionis Pharmaceuticals, Inc., Marina Biotech, Inc., Medestea Research & Production S.p.A., Novogen Limited, Pfizer Inc., Prothelia, Inc., SanBio, Inc., Santhera Pharmaceuticals Holding AG, Sarepta Therapeutics, Inc., Selecta Biosciences, Inc., Strykagen Corporation, Takeda Pharmaceutical Company Limited and WAVE Life Sciences Ltd. Drug Profiles mentioned in this research are ACE-083, Antisense Oligonucleotide to Inhibit DM1 Protein Kinase for Myotonic Dystrophy, Antisense RNAi Oligonucleotides for Myotonic Dystrophy, ATYR-1940, baliforsen, BIO-103, domagrozumab, Drugs for Merosin-Deficient Congenital Muscular Dystrophy Type 1A, elcatonin, Gene Therapy for Muscular Dystrophy and Liver Diseases, Gene Therapy to Activate Dysferlin for Duchenne and Limb Girdle Muscular Dystrophies, Gene Therapy to Activate Dysferlin for Dysferlinopathies, Gene Therapy to Activate Dystrophin for Muscular Dystrophy, IUCT-169, IUCT-290, IUCT-309, ketoprofen, LR-08, MED-1101, mexiletine hydrochloride, Oligonucleotide 1 to Target Dystrophia Myotonica Protein Kinase for Myotonic Dystrophy, Oligonucleotides to Inhibit DM1 Protein Kinase for Myotonic Dystrophy, omigapil, Pabparna, poloxamer, PRT-01, Recombinant Protein to Activate Utrophin for Muscular Dystrophies, RNAi Gene Therapy to Inhibit Myotilin for LGMD, RP-33, SB-308, SIWA-318, Small Molecule to Inhibit DUX4 for Muscular Dystrophy, Small Molecule to Target CUG RNA for Myotonic Dystrophy 1, Small Molecule to Target RNA for Myotonic Dystrophy, Small Molecules for Dysferlinopathies, Small Molecules for Facioscapulohumeral Muscular Dystrophy, Small Molecules for Myotonic Dystrophy, Small Molecules for Myotonic Dystrophy Type 1, Small Molecules to Activate SMCHD1 for Facioscapulohumeral Dystrophy, Small Molecules to Antagonize Glucocorticoid Receptor II for Muscular Dystrophy, Small Molecules to Inhibit MBNL1 for Myotonic Dystrophy Type I, Small Molecules to Target RNA for Myotonic Dystrophy, SRT-149, SRT-152, Stem Cell Therapy for Muscular Dystrophy, Stryka-232, Stryka-234, Stryka-425, Stryka-533, Stryka-978, tideglusib, trehalose, TXA-127, VAL-0411 and VAL-1205.
Order a opy of this report @ http://www.reportsnreports.com/purchase.aspx?name=755879 .
The Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Muscular Dystrophy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 5, 2, 24 and 14 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 3 and 4 molecules, respectively.Muscular Dystrophy.
Muscular Dystrophy (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Explore more reports on Pharmaceuticals.
ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 100+ leading global publishers & in-depth market research studies of over 5000 micro markets. With comprehensive information about the publishers and the industries for which they publish market research reports, we help you in your purchase decision by mapping your information needs with our huge collection of reports.
Contact: Ritesh Tiwari 2nd floor, metropole, Next to inox theatre, Bund garden road, Pune-411001 Maharashtra, India. Tel: +1-888-391-5441 firstname.lastname@example.org
Connect With Us on:
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All